Agents targeting proteins encoded by mutated EGFR, ALK, and ROS1 genes significantly improve the prognosis of advanced oncogene-driven non-small cell lung cancer (NSCLC) [1,2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.